About Roche
Roche is a venture capital firm founded in 1896. As of Nov 2021, Roche has invested in 75 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it led the $49M Series A round of GlycoEra along with 5AM Ventures. This round also saw participation from Sofinnova Partners and other investors.
Overall, Roche portfolio has seen 1 unicorn, 21 IPOs and 35 acquisitions including key companies like Horizon Discovery, Blueprint Medicines and Flatiron Health. A lot of funds co-invest with Roche, with names like SR One sharing a substantial percentage of its portfolio.
Roche has team of 6 people including 2 partners.
Key Metrics
Team Members
, &
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B &
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Roche's List of Top Investments
Roche has a portfolio of 75 companies, one of which is a Unicorn. Their most notable investments are in MacuLogix and Mission Therapeutics.Their portfolio spans across United States, Canada, ItalyÌý²¹²Ô»å 10 more locations. They have invested in Life Sciences, High Tech, HealthTechÌý²¹²Ô»å 3 other sectors, across stages such as Series A, Series B Ìý²¹²Ô»å 4 more. Here is the list of top investments by Roche:
Developer of cell lines with genetic modification using AAV gene-editing platform. The company has cell line engineering, knockout cell lines, and reporter cell lines. It also provides services in T cell activation assay, lymphocyte reaction assay, T cell-mediated tumor cell lysis assay, ADCC, and CDC assays, gene-editing for immuno-oncology, CRISPR Screening, drug combination screening, in vitro assay, and in-vivo assay.
Key facts about Horizon Discovery
- Founded Year: 2007
- Location: Cambridge (United Kingdom)
- Stage: Acquired
- Total Funding till date: $46.3M
- Employee Count: 432 as on Dec 31, 2019
- Investors: ValueAct Capital, Roche and 13 Others
- Latest Funding Round: Post IPO, Sep 07, 2018
- Highlight: Acquired
Developer of selective kinase inhibitors for patients with genomically defined cancers. Their approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Their ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets.
Key facts about Blueprint Medicines
- Founded Year: 2008
- Location: Cambridge (United States)
- Annual Revenue: $204M as on Dec 31, 2022
- Stage: Acquired
- Total Funding till date: $115M
- Employee Count: 201 as on Dec 31, 2022
- Investors: Ridgeback Capital Management, Roche and 19 Others
- Latest Funding Round: Post IPO, Jun 30, 2022, $1.25B
- Highlight: Acquired
Cloud-based practice management tool for providers. The company's OncologyCloud platform includes the electronic medical record for oncology, an analytics section for business clinical intelligence, a patient portal, and integrated billing management which allows cancer care providers and life sciences companies to track metrics related to cancer care, match patients to clinical trials and automate data collection.
Key facts about Flatiron Health
- Founded Year: 2012
- Location: New York City (United States)
- Last Known Valuation: $1.9B as on Feb 15, 2018
- Stage: Acquired
- Total Funding till date: $314M
- Employee Count: 1,067 as on Dec 31, 2023
- Investors: Roche, Darwin Ventures and 26 Others
- Latest Funding Round: Series C, Jan 06, 2016, $175M
- Highlight: Acquired
Developer of small molecule drugs for treating cancer. Its Degronimid platform incorporates highly selective small-molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural proteasome system. It has developed CFT7455 for treating hematologic malignancies, CFT8634 for sarcoma, BRAF V600E for slid tumors.
Key facts about C4 Therapeutics
- Founded Year: 2016
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $223M
- Employee Count: 121 as on Dec 31, 2022
- Investors: Roche, HTIF and 25 Others
- Latest Funding Round: Post IPO, Jan 04, 2024, $25M
- Highlight: Public
5.
Provider of genomics-based diagnostics test for cancer. The company's clinical assays, FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies and sarcomas, and the liquid biopsy test FoundationACT provide a complete genomic profile of cancers, which oncologists can use to inform their treatment decisions. In addition, all tests provide an estimate of tumor mutational burden that enables oncologists to predict immunotherapy response as well.
Key facts about Foundation Medicine
- Founded Year: 2010
- Location: Cambridge (United States)
- Annual Revenue: $153M as on Dec 31, 2017
- Stage: Acquired
- Total Funding till date: $96.5M
- Employee Count: 1,707 as on Dec 31, 2022
- Investors: Ridgeback Capital Management, Roche and
- Latest Funding Round: Series B, Jan 08, 2013, $13.5M
- Highlight: Acquired
Roche's Year-on-Year Investment Trends
Roche has invested in 75 companies over the last 21 years, with an average of 3 new investments annually in the last 10 years. Its most recent first time investment was in GlycoEra and most recent follow-on round was in Vaxcyte.
Year | No. of Investments | ||
|---|---|---|---|
1stÌý¸é´Ç³Ü²Ô»å | Follow-on | Total | |
2025 (YTD) | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 2 | 0 | 2 |
2020 | 1 | 2 | 3 |
2019 | 1 | 3 | 4 |
2018 | 7 | 1 | 8 |
2017 | 4 | 2 | 6 |
2016 | 8 | 1 | 9 |
Get Roche's portfolio delivered to your inbox!
Roche's Investments by Stage
Roche has made 19 investments in Series A stage with an average round size of $36.7M, 17 investments in Series B stage with an average round size of $33.4M and 5 investments in Series C stage with an average round size of $119M.Note: We have considered here, only first round of investments
Stage of entry | No. of Investments |
|---|---|
Series A | 19 |
Series B | 17 |
Series C | 5 |
Series D | 3 |
Post IPO | 2 |
Others | 1 |
Roche's Investments by Sector
Roche has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Sustainability Tech. Notably, it has invested in 61 Tech companies, 54 Enterprise (B2B) companies, 5 Software companies and at least 3 companies focusing on Consumer (B2C).
Note: We have considered here, only first round of investments
Sector | No. of Investments |
|---|---|
Life Sciences | 41 |
High Tech | 14 |
HealthTech | 7 |
Enterprise Applications | 5 |
Sustainability Tech | 5 |
Others | 8 |
Roche's Investments by Geography
Roche has made most investments in United States (38), followed by United Kingdom where it has made 2 investments.
Note: We have considered here, only first round of investments
Country | No. of Investments |
|---|---|
United States | 38 |
United Kingdom | 2 |
Austria | 1 |
Denmark | 1 |
France | 1 |
Others | 4 |
Roche's recent investments
Here are the most recent investments by Roche:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 05, 2021 | Switzerland | Series A | $49M | 5AM Ventures [+2] | |
Jan 28, 2021 | Italy | Series A | $8.49M | Sofinnova Partners [+3] | |
Aug 26, 2020 | United States | Series C | $270M | [+20] | |
Apr 03, 2020 | United States | Series D | $110M | ||
Jan 10, 2020 | United States | Series B | $125M | Wellington [+6] |
Get the detailed list of all investments by Roche. Download now!Unicorns in Roche's Portfolio
Here is a list of unicorns in Roche's portfolio:
ÃØÃÜÑо¿Ëù Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
67 | Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | San Francisco | Series E | swvphyp |
IPOs and Publicly Listed companies in Roche's Portfolio
Here are Roche's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 29, 2021 | Dec 22, 2018 | Series A | $59M | |
Jun 16, 2021 | - | - | - | |
Oct 16, 2020 | 2018 | Series A | $100M | |
Oct 02, 2020 | Jan 07, 2016 | Series A | $73M | |
Jun 12, 2020 | Jul 23, 2015 | Series A | $22M |
Acquired companies in Roche's Portfolio
Here are Roche's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 02, 2025 | - | - | - | |
Apr 16, 2025 | Jun 08, 2016 | Series B | $23M | |
Jan 13, 2025 | Nov 14, 2017 | Series D | $30M | |
Jan 08, 2024 | Jul 05, 2006 | Series C | $55M | |
Nov 28, 2022 | Jun 01, 2018 | Series A | $26.4M |
Team profile of Roche
Roche has a team of 6 membersÌýincluding 2 Partners and 3 PrincipalsÌýlocated in Switzerland and United States. Roche's team does not sit on the board of any company as of now.Here is a list of all team members in Roche:
Name | Designation | Location | Board Memberships | Contact details |
|---|---|---|---|---|
Partner | - | - | - | |
Principal | Basel | - | - | |
Principal | Basel | - | ||
Associate | San Francisco | - | - |
Get the full list of Roche's team & partners for free. Download now!Co-investors of Roche
Over the past 21 years, 379 investors have co-invested in Roche's portfolio companies.
- Invested before Roche:ÌýHHS, Google Ventures and 113 others have invested in rounds before Roche. There are 6 companies where HHS has invested before Roche and 3 companies where Google Ventures has invested before Roche.
- Top Co-investors of Roche:Ìý122 investors entered a company along with Roche. These include investors like SR One (6 companies).
- Invested after Roche:ÌýA total of 142 investors have invested in Roche's portfolio after their investments. Top Investors include Roche (7 companies), Adage Capital Management (4 companies) and RA Capital Management (4 companies).
Get full list of Roche's co-investors delivered to your inbox!
Recent News related to Roche
•
GlobeNewswire•Jan 10, 2020•Wellington, Janus Henderson Investors, Boxer Capital, Pivotal bioVenture Partners China and 6 others
•
•
•
Rttnews•Jun 22, 2018•Roche
•
•
BioCentury•Feb 02, 2018•Roche
•
•
BioSpace•Nov 16, 2017•Roche
